122
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources

, , ORCID Icon, &
Pages 149-158 | Published online: 29 Jan 2021
 

Abstract

Background

Dimethyl fumarate (DMF) has shown efficacy in reducing relapse rates in patients with multiple sclerosis (MS). However, associated adverse effects (AE) such as gastrointestinal (GI) AE, flushing and lymphopenia are the main cause of treatment discontinuation. The aim of this study was to evaluate the effectiveness of DMF, and to assess strategies to reduce treatment discontinuation rates in routine clinical practice.

Patients and Methods

Ninety patients started DMF treatment between August 2015 and February 2020. Prior to DMF therapy, patients received written information regarding treatment and the management of AE, along with medical prescriptions. Clinical and analytical data were collected at clinical visits performed at least 6-monthly, and disease progression was evaluated by brain magnetic resonance imaging (MRI).

Results

Prior to DMF, 78.7% of patients had an annualized relapse rate (ARR) of 1.07 (range: 1–3) and median Expanded Disability Status Scale (EDSS) score of 1.0 (range: 0–2). At final follow-up, ARR and median EDSS scores were significantly reduced to 0.09 (range: 0–2; p< 0.001) and 0 (range: 0–1.625; p< 0.001), respectively. Just over one quarter of patients with brain MRI (26.8% of 71 patients) showed improvement in disease activity based on MRI evaluation. Lymphopenia was associated with previous treatment lines (p=0.042) and longer disease duration (p=0.032). A total of twelve patients abandoned DMF treatment, mainly due to lymphopenia (7.9%), but none did it because of GI AE or flushing.

Conclusion

In our series, DMF showed high clinical and radiological efficacy. Providing patients with complete information prior to treatment on the management of associated AE helps them to better understand what to expect, improves tolerance and reduces clinical and telephone consultations, which may help to reduce the use and cost of healthcare resources.

Acknowledgments

The authors thank Dr. Susana Cañón, Medical Statistics Consulting S. L. (MSC) for the scientific writing of the manuscript and Biogen for providing us with this service.

Disclosure

A. Rodríguez-Regal has received compensation from Genzyme, Roche, Novartis, Sanofi, Biogen and TEVA for services as consultant. L. Ramos-Rúa and C. Amigo-Jorrín have received compensation from Genzyme, Roche, Novartis and Biogen for service as consultants. L. Anibarro-García has received compensation from Genzyme for services as consultant. A. Lopez Real has received compensation from Genzyme, Roche, Biogen and TEVA for services as consultant. The authors report no other conflicts of interest in this work.

Additional information

Funding

This study has not been funded by any public or private body.